ven as a trained biochemist/molecular biologist, reading the article by Lin et al (1) in this issue of Critical Care Medicine required considerable focus. However, amidst the alphabet soup of abbreviations, double negatives, and signaling pathway complexity lays novel information that ultimately may inform our clinical approach to understanding and treating acute respiratory distress syndrome (ARDS).
As the authors point out in their introductory section, ARDS-associated acute pulmonary edema is a function not only of diffuse pulmonary capillary leak but also of impaired alveolar fluid clearance. Treatment of ARDS has largely been supportive in terms of providing mechanical ventilation and avoidance of fluid overload while the lungs undergo repair. It remains unclear if intervention with corticosteroids is beneficial in this setting (2, 3) . Although completely basic science in its conduct, the study by Lin et al (1) encourages us to speculate that modulation of alveolar fluid clearance may represent another therapeutic intervention for ARDS.
In their investigation, the authors utilized a murine hyperoxia-exposure lung injury model that reproducibly results in acute hypoxemic respiratory failure associated with pulmonary edema. At the onset, it is important to understand the molecular components being investigated. With-no-lysine-kinase (WNK) is the focus of investigation. Although its own activation remains somewhat unclear, this investigation examined the WNK downstream pathway that involves phosphorylation of another kinase termed STE20/ SPS1-related proline/alanine-rich kinase (SPAK) and in turn phosphorylation activation of the sodium-potassiumchloride cotransporter (NKCC). The authors point out that alveolar fluid clearance likely involves a number of mechanisms including an epithelial sodium channel, a cystic fibrosis transmembrane conductance regulator, a sodium/potassium ATPase, and the NKCC. The authors utilized well-established methodology in the murine hyperoxia model to derive a number of findings that support the role of the WNK-SPAK-NKCC pathway in alveolar fluid regulation.
The hyperoxia model results in acute pulmonary edema in mice following 60 hours of exposure to 100% oxygen and activates WNK and SPAK expressions and the NKCC as well as the epithelial sodium channel. It is crucial to understand that increased activity of the epithelial sodium channel leads to enhanced alveolar fluid clearance, while activation of the NKCC results in impaired alveolar fluid clearance (4, 5) . This biologic couplet provides an example of a servo mechanism that is likely involved in tight regulation of fluid balance within the alveolus. Ultimately, the investigators demonstrate that in their model, the abundance of the WNK is increased concomitant with increased phosphorylation (activation) of the SPAK, all of which is associated with increased phosphorylation (activation) of the NKCC. This gain of function of the cotransporter is associated with fluid and ion retention within the alveolus and hence reduced alveolar fluid clearance. Concomitantly, the investigators show that the same hyperoxia stimulus enhances the activity of the epithelial sodium channel that would have the opposite effect, namely increasing alveolar fluid clearance. If mice with a double knockout of the SPAK gene are utilized in the experiment, then the phosphorylation of the NKCC is decreased, the cotransporter is less activated, and hence, there is less fluid and ion retention in the alveolus. A similar effect was demonstrated by treating the animals with nebulized furosemide, which inhibits NKCC function with a resultant effect similar to that seen in the SPAK double-knockout mice.
These intricate but elegant series of experiments illustrate the complexity of intracellular signaling involved in biologic processes, in this case alveolar fluid clearance. For the clinician, this basic science report provides a possible new therapeutic intervention for acute pulmonary edema, specifically nebulized furosemide. The authors point out that the effect of nebulized furosemide was likely isolated to the lungs, as this intervention had no effect on animal weight or urine output. However, as a cautionary note, although β 2 -adrenergic therapy to enhance the activity of the alveolar sodium-potassium ATPase was shown to be beneficial in a variety of preclinical settings, a definitive clinical trial among patients with ARDS did not demonstrate benefit (6) . However, that approach really addressed only one side of the equation. It is possible that inhibiting the NKCC, for example, with nebulized furosemide Using the Body's Radiator Following Cardiac Arrest: How Cool Is That …?* P ulmonary gas exchange utilizing liquid breathing with perfluorocarbons has been investigated over the past five decades (1) . Perfluorocarbons are unique fluids which are inert and colorless, have a density approximately twice that of water, have a low surface tension with air (15-19 dynes/cm), and carry large quantities of oxygen (~50 mL of oxygen/dL of perfluorocarbon) and carbon dioxide (140-210 mL of carbon dioxide/dL of perfluorocarbon) (1, 2) . Two effective methods of liquid ventilation have been developed: 1) total liquid ventilation (TLV) in which the lungs are filled and then ventilated with tidal volumes of perfluorocarbon using a "liquid ventilator" and 2) partial liquid ventilation (PLV) in which the lungs are gas ventilated using a standard gas mechanical ventilator after filling of the lungs with perfluorocarbon. Studies over the past 20 years have evaluated PLV in the management of respiratory failure without demonstrating effectiveness, although the jury remains out with regard to application in certain subgroups, such as newborns in the setting of the respiratory distress syndrome associated with prematurity. A number of centers continue to integrate PLV/lung lavage with perfluorocarbons and extracorporeal life support (ECLS and extracorporeal membrane oxygenation) in the management of severe respiratory failure with encouraging anecdotal results. However, what has not been well explored is TLV. In animal studies, the ability to augment pulmonary function and gas exchange along with effective lavage of the lungs in severe respiratory failure models is remarkable.
In this issue of Critical Care Medicine, Kohlhauer et al (3) have applied TLV to achieve rapid whole-body cooling to 32°C, starting 5 minutes after return of spontaneous circulation (ROSC) using an asphyxia model of cardiac arrest in rabbits. They demonstrate enhanced survival and reduced neurologic dysfunction, brain lesion scores, and blood-brain barrier disruption in the TLV when compared with control animals and those managed with intravascular cold saline infusion. Brain, heart, and kidney reactive oxygen species and serum inflammatory markers were reduced in the TLV group when compared with the other groups. Given that cooling in the setting of cardiac arrest appears to be of benefit, the most relevant scientific question answered by this study is whether more rapid cooling is of value. In this animal model and following ROSC, the answer appears to be a resounding, "Yes": cooling within approximately 30 minutes results in enhanced survival and neurologic outcomes when compared with cold saline infusion, which allows cooling over ~120 minutes, or in normothermic animals.
Traditionally, rapid cooling or warming has been performed on extracorporeal support with the ability to directly affect and augmenting the sodium-potassium ATPase with β 2adrenergic agonists could simultaneously reduce alveolar fluid and ion retention and enhance ion and water transport out of the alveolus. The approach seems logical with both of the pharmacologic interventions relatively nontoxic, particularly when provided with local nebulized drug delivery.
In summary, Lin et al (1) provide us with new information that further untangles water and ion regulation in the alveolus. Deciphering the complex, redundant, interconnected signaling pathways involved in biologic processes can only really be undertaken with these types of investigations. Hopefully, these positive findings will eventually make their way to translational investigations. It would be nice to have a pharmacologic intervention to augment to mechanical ventilation support for our patients with ARDS.
